{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:21Z","timestamp":1784759421569,"version":"3.55.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30AG024827"],"award-info":[{"award-number":["P30AG024827"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01AG081466"],"award-info":[{"award-number":["R01AG081466"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The evidence and scientific guidance regarding the efficacy of combination treatment strategies for osteoporosis is currently limited. We performed a systematic review of primary studies that evaluated the effect of combination bone-active medication therapy on BMD and\/or fracture outcomes. Eleven studies that assessed 7 different combinations of medications were included. Evidence for superior efficacy of combination treatment compared with monotherapy was strong for only 3 medication combinations: teriparatide and denosumab, teriparatide and zoledronic acid, and alendronate and raloxifene. Three small studies that evaluated combination teriparatide and denosumab found evidence of statistically significant benefit for increasing BMD at the lumbar spine and\/or hip more than either medication alone. One large study that evaluated combination teriparatide and zoledronic acid found that after 1\u00a0yr of treatment BMD at the lumbar spine increased significantly more in the combination treatment group than the zoledronic acid alone group, and BMD at the hip increased significantly more in the combination treatment group than the teriparatide alone group. This study also found significantly reduced risk of clinical fractures with combination therapy compared with zoledronic acid alone, but not when compared with teriparatide alone. Two studies that evaluated combination alendronate and raloxifene found evidence of significant benefit on BMD outcomes. We found insufficient evidence for superior efficacy of other bone-active medication combinations compared with monotherapy on either BMD outcomes or the very limited data on fracture outcomes. In conclusion, there is evidence supporting the use of combination treatment with teriparatide and denosumab, teriparatide and zoledronic acid, and alendronate and raloxifene for osteoporosis for increasing BMD more than monotherapy, although several of the studies showing benefit of these combinations are small, and data are lacking on fracture outcomes. These combinations can be considered for treatment of patients with osteoporosis; however, further larger studies would be useful to evaluate fracture outcomes as well as other combinations for potential efficacy.<\/jats:p>","DOI":"10.1093\/jbmrpl\/ziaf165","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T12:17:38Z","timestamp":1760703458000},"source":"Crossref","is-referenced-by-count":5,"title":["A systematic review of combination treatment strategies for osteoporosis"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6220-4696","authenticated-orcid":false,"given":"Smita","family":"Nayak","sequence":"first","affiliation":[{"name":"Berkeley Madonna, Inc. , Albany, CA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan L","family":"Greenspan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine , Pittsburgh, PA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"issue":"11","key":"2025111608423790600_ref1","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","article-title":"The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine","volume":"29","author":"Wright","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2025111608423790600_ref2","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","year":"2000","journal-title":"NIH Consens Statement"},{"issue":"3","key":"2025111608423790600_ref3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025111608423790600_ref4","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1177\/1060028020970518","article-title":"Economic burden of osteoporosis-related fractures in the US medicare population","volume":"55","author":"Williams","year":"2021","journal-title":"Ann Pharmacother"},{"issue":"9","key":"2025111608423790600_ref5","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1007\/s00198-010-1480-2","article-title":"Mortality rates after incident non-traumatic fractures in older men and women","volume":"22","author":"Morin","year":"2011","journal-title":"Osteoporos Int"},{"issue":"10","key":"2025111608423790600_ref6","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","article-title":"The clinician's guide to prevention and treatment of osteoporosis","volume":"33","author":"LeBoff","year":"2022","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"2025111608423790600_ref7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"American Association of Clinical Endocrinologists\/American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract"},{"issue":"1","key":"2025111608423790600_ref8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.7326\/M19-0961","article-title":"National Institutes of Health pathways to prevention workshop: research gaps for long-term drug therapies for osteoporotic fracture prevention","volume":"171","author":"Siu","year":"2019","journal-title":"Ann Intern Med"},{"issue":"oct18 2","key":"2025111608423790600_ref9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"issue":"3","key":"2025111608423790600_ref10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","article-title":"Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2025111608423790600_ref11","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1210\/jc.2015-1715","article-title":"Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate","volume":"100","author":"Cosman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025111608423790600_ref12","doi-asserted-by":"publisher","first-page":"3772","DOI":"10.1210\/jc.2008-2719","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent","volume":"94","author":"Cosman","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025111608423790600_ref13","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.otsr.2018.07.015","article-title":"Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion","volume":"104","author":"Ide","year":"2018","journal-title":"Orthop Traumatol Surg Res"},{"issue":"11","key":"2025111608423790600_ref14","doi-asserted-by":"publisher","first-page":"3301","DOI":"10.1007\/s00198-016-3647-y","article-title":"Teriparatide and denosumab combination therapy and skeletal metabolism","volume":"27","author":"Idolazzi","year":"2016","journal-title":"Osteoporos Int"},{"issue":"3","key":"2025111608423790600_ref15","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1210\/jcem.87.3.8325","article-title":"Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis","volume":"87","author":"Johnell","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025111608423790600_ref16","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","article-title":"Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (the DATA extension study): a randomized controlled trial","volume":"99","author":"Leder","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"9886","key":"2025111608423790600_ref17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"2025111608423790600_ref18","doi-asserted-by":"crossref","first-page":"16055","DOI":"10.1038\/boneres.2016.55","article-title":"Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women","volume":"5","author":"Nakamura","year":"2017","journal-title":"Bone Res"},{"issue":"4","key":"2025111608423790600_ref19","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1080\/14397595.2018.1524997","article-title":"Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women","volume":"29","author":"Suzuki","year":"2019","journal-title":"Mod Rheumatol"},{"issue":"1","key":"2025111608423790600_ref20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.6118\/jmm.2017.23.1.56","article-title":"Combination therapy of raloxifene and alendronate for treatment of osteoporosis in elderly women","volume":"23","author":"Um","year":"2017","journal-title":"J Menopausal Med"},{"issue":"1","key":"2025111608423790600_ref21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s12020-012-9819-4","article-title":"Combination therapy with risedronate and teriparatide in male osteoporosis","volume":"44","author":"Walker","year":"2013","journal-title":"Endocrine."},{"issue":"1","key":"2025111608423790600_ref22","first-page":"51","article-title":"Efficacy of bisphosphonates combined with recombinant human parathyroid hormone 1-34 in elderly patients with lumbar or hip joint injury caused by osteoporosis","volume":"38","author":"Ziying","year":"2019","journal-title":"Lat Am J Pharm"},{"issue":"1","key":"2025111608423790600_ref23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s00198-018-4790-4","article-title":"Combination therapy with parathyroid hormone analogs and antiresorptive agents for osteoporosis: a systematic review and meta-analysis of randomized controlled trials","volume":"30","author":"Lou","year":"2019","journal-title":"Osteoporos Int"},{"issue":"4","key":"2025111608423790600_ref24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/jbmr.3641","article-title":"Change in bone density and reduction in fracture risk: a meta-regression of published trials","volume":"34","author":"Bouxsein","year":"2019","journal-title":"J Bone Miner Res"}],"container-title":["JBMR Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jbmrplus\/advance-article-pdf\/doi\/10.1093\/jbmrpl\/ziaf165\/64856492\/ziaf165.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/12\/ziaf165\/64856492\/ziaf165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article-pdf\/9\/12\/ziaf165\/64856492\/ziaf165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T13:42:42Z","timestamp":1763300562000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmrplus\/article\/doi\/10.1093\/jbmrpl\/ziaf165\/8296965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf165","relation":{},"ISSN":["2473-4039"],"issn-type":[{"value":"2473-4039","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,22]]},"article-number":"ziaf165"}}